The 56 Point TA; Charts With an Attitude Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : The 56 Point TA; Charts With an Attitude

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Doug R who wrote (31990)	9/14/1999 9:15:00 AM
From: John Miz	Read Replies (1) of 79214

ALLP NEWS> biz.yahoo.com SAN DIEGO--(BW HealthWire)--Sept. 14, 1999--Alliance Pharmaceutical Corp. (Nasdaq:ALLP - news) announced today that it has reached agreement with the Food and Drug Administration (FDA) on the key design features of the Phase 3 program for Oxygent(TM), an intravascular oxygen carrier (''blood substitute'') intended to reduce the need for donor blood transfusions in surgical patients. Oxygent will be studied in a Phase 3 clinical (human) trial in the U.S. involving patients undergoing coronary artery bypass grafting (CABG) surgery under cardiopulmonary bypass (CPB). This study, which is expected to start shortly, will complement a Phase 3 trial currently underway with general surgery patients in eight European countries. Oxygent is the only blood substitute in clinical development that is formulated from a synthetic raw material (emulsified perflubron) and not derived from human or bovine blood.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next